Market Place
In case you haven’t had time to follow the Mylan-Teva, Perrigo-Mylan saga of the past few weeks, we compiled a quick set of facts for your speed read needs:
Table: Perrigo & Mylan versus Mylan & Teva:
|
Fast Fact |
World’s largest manufacturer of OTC healthcare products for the store brand market |
Holds the number one ranking in the U.S. generics prescription market in terms of sales |
Teva is the world’s largest generic medicines producer |
|
|
Annual Revenues (2014) |
||||
|
Size of their generics business |
||||
|
Top products |
Tysbari® |
|||
|
2013 Acquisitions |
DEC-2013: Elan Pharmaceuticals |
FEB-2013: Agila Specialties |
||
|
|
||||
|
(Tax inversion) |
||||
|
2014 Acquisitions |
JUL-2014: Abbott’s non-US generics business $5.3 billion (tax inversion) |
|||
|
SEPT-2014: Arixtra® rights |
||||
|
2015 Acquisitions |
FEB-2015: |
MAR-2015: Auspex |
||
| April 2015 | ||||
|
Perrigo has rejected 3 takeover offers from Mylan. They first valued Perrigo at just under $29 billion, the next at $33 billion and the last one at $35.6 billion. |
Mylan rejected Teva’s unsolicited $40 billion bid for Mylan, 50% in cash and 50% in stock. Teva valued Mylan at $82/share. |
|||
If Mylan’s takeover of Perrigo fails, there is a high possibility that Teva, in its quest for growth, will eventually acquire Mylan. However, the highlight of this month long saga, has been the over 3,000 word letter Mylan’s Executive Chairman wrote when rejecting the Teva deal (Mylan internally refers to Teva stock as “toilet paper”).
Mylan’s Board answered that financially, Teva’s offer, does not even come close to qualify as a proposal worth pursuing (starting point of discussion - excess of $100 per share). Other concerns were also cited such as: Mylan having a substantial business in India, while Teva has a limited presence, and has been disparaging about India’s products and culture. In addition, should the deal come through, the massive overlapping positions would create significant antitrust concerns.
On the other hand, here are some comments from the response of Mylan. Take your pick on what you think hurt the most:
* “Mylan would give Teva severe indigestion”.
* We believe Teva shares to be “low-quality and high-risk currency”.
* Teva is offering Mylan shareholders to “take stock of a poorly performing troubled company in a combination that lacks industrial logic and is a terrible cultural fit”.
* There is “persistent turnover and turmoil amongst the Teva leadership and Board”, “strategic confusion” and Teva’s under performance is “directly attributed to its “dysfunctional” culture”.
* The Board was described “like a Nuthouse” and ran the only CEO with pharmaceutical experience out of town within 18 months of being on the job
* “Do not wish to make Teva’s problems Mylan’s problems”
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : ppp007 - toilet paper by opethpainter is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
